We focus on translational molecular imaging with PET and PET/MRI and on development of targeted radionuclide therapies (theranostics) for use in precision medicine in cancer, cardiovascular diseases and inflammatory disease.
We have expertise in all the steps involved in developing molecular imaging: from basic research to obtaining approval by the health authorities, GMP and GCP. Access to both clinical and preclinical state-of-the-art facilities allows us to perform highly translational research based on relevant clinical challenges. Several of CMI’s results have been implemented in clinical routine.
Development of molecular imaging involves numerous disciplines; therefore, we have researchers from diverse backgrounds: physicists, chemists, engineers, human biologists, medical doctors, veterinarians, etc.
For more information, please visit the Kjær Group site.